Hepatitis B and C

Wikrom W Karnsakul; Kathleen Schwarz

doi:10.1016/j.pcl.2017.01.007

Hepatitis B and C

Wikrom W Karnsakul, Kathleen Schwarz

School of Medicine

Research output: Contribution to journal › Review article

Abstract

Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.

Original language	English (US)
Pages (from-to)	641-658
Number of pages	18
Journal	Pediatric Clinics of North America
Volume	64
Issue number	3
DOIs	https://doi.org/10.1016/j.pcl.2017.01.007
State	Published - Jun 1 2017

Keywords

Direct-acting antiviral agents
Hepatitis B
Hepatitis C
Pegylated interferon
Spontaneous viral clearance
Sustained virologic response

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Medicine(all)

Access to Document

10.1016/j.pcl.2017.01.007

Fingerprint Dive into the research topics of 'Hepatitis B and C'. Together they form a unique fingerprint.

Cite this

Karnsakul, W. W., & Schwarz, K. (2017). Hepatitis B and C. Pediatric Clinics of North America, 64(3), 641-658. https://doi.org/10.1016/j.pcl.2017.01.007

@article{e8897738c189436db08fb94d49767279,

title = "Hepatitis B and C",

abstract = "Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.",

keywords = "Direct-acting antiviral agents, Hepatitis B, Hepatitis C, Pegylated interferon, Spontaneous viral clearance, Sustained virologic response",

author = "Karnsakul, {Wikrom W} and Kathleen Schwarz",

year = "2017",

month = jun,

day = "1",

doi = "10.1016/j.pcl.2017.01.007",

language = "English (US)",

volume = "64",

pages = "641--658",

journal = "Pediatric Clinics of North America",

issn = "0031-3955",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Hepatitis B and C

AU - Karnsakul, Wikrom W

AU - Schwarz, Kathleen

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.

AB - Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.

KW - Direct-acting antiviral agents

KW - Hepatitis B

KW - Hepatitis C

KW - Pegylated interferon

KW - Spontaneous viral clearance

KW - Sustained virologic response

UR - http://www.scopus.com/inward/record.url?scp=85019210575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019210575&partnerID=8YFLogxK

U2 - 10.1016/j.pcl.2017.01.007

DO - 10.1016/j.pcl.2017.01.007

M3 - Review article

C2 - 28502443

AN - SCOPUS:85019210575

VL - 64

SP - 641

EP - 658

JO - Pediatric Clinics of North America

JF - Pediatric Clinics of North America

SN - 0031-3955

IS - 3

ER -